K Pharma,Inc. (TYO:4896)

K Pharma,Inc. Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,504	2,268	3,266	1,336	188
Cash & Short-Term Investments	1,504	2,268	3,266	1,336	188
Cash Growth	-40.20%	-30.56%	144.46%	610.64%	-
Inventory	7	5	10	10	9
Prepaid Expenses	102	39	31	22	6
Other Current Assets	22	36	1	2	1
Total Current Assets	1,635	2,348	3,308	1,370	204
Long-Term Investments	48	4	4	3	1
Other Long-Term Assets	-	1	1	1	-
Total Assets	1,683	2,353	3,313	1,374	205
Accounts Payable	9	10	11	10	2
Accrued Expenses	52	48	30	21	17
Current Income Taxes Payable	3	1	76	1	-
Other Current Liabilities	9	4	61	1	4
Total Current Liabilities	73	63	178	33	23
Other Long-Term Liabilities	34	32	31	5	4
Total Liabilities	107	95	209	38	27
Common Stock	10	100	854	100	100
Additional Paid-In Capital	2,248	3,004	3,003	2,249	699
Retained Earnings	-681	-846	-752	-1,012	-620
Comprehensive Income & Other	-1	-	-1	-1	-1
Shareholders' Equity	1,576	2,258	3,104	1,336	178
Total Liabilities & Equity	1,683	2,353	3,313	1,374	205
Net Cash (Debt)	1,504	2,268	3,266	1,336	188
Net Cash Growth	-40.20%	-30.56%	144.46%	610.64%	-
Net Cash Per Share	129.60	195.44	289.79	143.18	24.73
Filing Date Shares Outstanding	11.6	11.6	11.32	9.33	7.6
Total Common Shares Outstanding	11.6	11.6	11.32	9.33	7.6
Working Capital	1,562	2,285	3,130	1,337	181
Book Value Per Share	135.81	194.58	274.20	143.18	23.42
Tangible Book Value	1,576	2,258	3,104	1,336	178
Tangible Book Value Per Share	135.81	194.58	274.20	143.18	23.42

Source: S&P Global Market Intelligence. Standard template. Financial Sources.